European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: The SHARE initiative

Annals of the Rheumatic Diseases

Volumn 76, Issue 10, 2017, Pages 1637-1641

  Groot, Noortje ^a,b   De Graeff, Nienke ^a   Avcin, Tadej ^c   Bader Meunier, Brigitte ^d   Dolezalova, Pavla ^e   Feldman, Brian ^f   Kenet, Gili ^g   Koné Paut, Isabelle ^h   Lahdenne, Pekka ⁱ   Marks, Stephen D ^j   McCann, Liza ^k,l   Pilkington, Clarissa A ^j   Ravelli, Angelo ^m   Van Royen Kerkhof, Annet ^a   Uziel, Yosef ⁿ   Vastert, Sebastiaan J ^a   Wulffraat, Nico M ^a   Ozen, Seza ^o   Brogan, Paul ^j   Kamphuis, Sylvia ^b   Beresford, Michael W ^k,l   more..

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c UNIVERSITY CHILDREN S HOSPITAL   (Slovenia)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e CHARLES UNIVERSITY   (Czech Republic)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

^g SHEBA MEDICAL CENTER   (Israel)

^h BICÊTRE HOSPITAL   (France)

ⁱ UNIVERSITY OF HELSINKI   (Finland)

^j GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^k ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^l UNIVERSITY OF LIVERPOOL   (United Kingdom)

^m UNIVERSITY OF GENOA   (Italy)

ⁿ TEL AVIV UNIVERSITY   (Israel)

^o HACETTEPE UNIVERSITY   (Turkey)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BIOLOGICAL PRODUCT; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; ECULIZUMAB; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PHOSPHOLIPID ANTIBODY; RITUXIMAB;

ANTIBODY SCREENING; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME; CHILDHOOD DISEASE; DISEASE CLASSIFICATION; EUROPEAN; EVIDENCE BASED PRACTICE; HEALTH CARE ORGANIZATION; HEMATOLOGY; HEPARINIZATION; HUMAN; MEDICAL EXPERT; META ANALYSIS (TOPIC); PLASMA EXCHANGE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOLOGIST; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS PREVENTION; VEIN THROMBOSIS; ADOLESCENT; CHILD; EVIDENCE BASED MEDICINE; INFANT; NEWBORN; PRESCHOOL CHILD;

ADOLESCENT; ANTIPHOSPHOLIPID SYNDROME; CHILD; CHILD, PRESCHOOL; EVIDENCE-BASED MEDICINE; HUMANS; INFANT; INFANT, NEWBORN;

EID: 85030620432     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2016-211001     Document Type: Article

References (54)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
2. Avcin T, Cimaz R, Rozman B. Ped-APS Registry Collaborative Group. The Ped-APS registry: the antiphospholipid syndrome in childhood. Lupus 2009;18:894-9.
3. Avcin T, Cimaz R, Silverman ED, et al. Pediatric antiphospholipid syndrome: clinical and immunologic features of 121 patients in an international registry. Pediatrics 2008;122:e1100-7.
4. Cimaz R, Descloux E. Pediatric antiphospholipid syndrome. Rheum Dis Clin North Am 2006;32:553-73.
5. Descloux E, Durieu I, Cochat P, et al. Paediatric systemic lupus erythematosus: prognostic impact of antiphospholipid antibodies. Rheumatology 2008;47:183-7.
6. Ravelli A, Martini A. Antiphospholipid antibody syndrome in pediatric patients. Rheum Dis Clin North Am 1997;23:657-76.
7. Sebastiani GD, Iuliano A, Cantarini L, et al. Genetic aspects of the antiphospholipid syndrome: an update. Autoimmun Rev 2016;15:433-9.
8. Shoenfeld Y, Meroni PL, Toubi E. Antiphospholipid syndrome and systemic lupus erythematosus: are they separate entities or just clinical presentations on the same scale? Curr Opin Rheumatol 2009;21:495-500.
9. Tincani A, Andreoli L, Chighizola C, et al. The interplay between the antiphospholipid syndrome and systemic lupus erythematosus. Autoimmunity 2009;42:257-9.
10. Wulffraat NM, Vastert B, SHARE consortium. Time to share. Pediatr Rheumatol Online J 2013;11:5.
11. Enders FB, Bader-Meunier B, Baildam E, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis 2017;76:329-40.
12. Giancane G, Ter Haar NM, Wulffraat N, et al. Evidence-based recommendations for genetic diagnosis of familial mediterranean fever. Ann Rheum Dis 2015;74:635-41.
13. ter Haar NM, Oswald M, Jeyaratnam J, et al. Recommendations for the management of autoinflammatory diseases. Ann Rheum Dis 2015;74:1636-44.
14. Dougados M, Betteridge N, Burmester GR, et al; EULAR. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004;63:1172-6.
15. Zhang W, Doherty M, Bardin T, et al; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.
16. Zhang W, Doherty M, Pascual E, et al; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301-11.
17. Delbecq AL, Van de Ven AH. A group process model for problem identification and program planning. J Appl Behav Sci 1971;7:466-92.
18. Angelini L, Rumi V, Nardocci N, et al. Hemidystonia symptomatic of primary antiphospholipid syndrome in childhood. Mov Disord 1993;8:383-6.
19. Cervera R, Asherson RA, Font J, et al. Chorea in the antiphospholipid syndrome. Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine 1997;76:203-12.
20. Espinosa G, Font J, García-Pagan JC, et al. Budd-Chiari syndrome secondary to antiphospholipid syndrome: clinical and immunologic characteristics of 43 patients. Medicine 2001;80:345-54.
21. Kiechl-Kohlendorfer U, Ellemunter H, Kiechl S. Chorea as the presenting clinical feature of primary antiphospholipid syndrome in childhood. Neuropediatrics 1999;30:96-8.
22. Takanashi J, Sugita K, Miyazato S, et al. Antiphospholipid antibody syndrome in childhood strokes. Pediatr Neurol 1995;13:323-6.
23. Berkun Y, Padeh S, Barash J, et al. Antiphospholipid syndrome and recurrent thrombosis in children. Arthritis Rheum 2006;55:850-5.
24. Gattorno M, Falcini F, Ravelli A, et al. Outcome of primary antiphospholipid syndrome in childhood. Lupus 2003;12:449-53.
25. Zamora-Ustaran A, Escarcega-Alarcón RO, Garcia-Carrasco M, et al. Antiphospholipid syndrome in mexican children. Isr Med Assoc J 2012;14:286-9.
26. Ahluwalia J, Singh S, Naseem S, et al. Antiphospholipid antibodies in children with systemic lupus erythematosus: a long-term clinical and laboratory follow-up status study from northwest India. Rheumatol Int 2014;34:669-73.
27. Berube C, Mitchell L, Silverman E, et al. The relationship of antiphospholipid antibodies to thromboembolic events in pediatric patients with systemic lupus erythematosus: a cross-sectional study. Pediatr Res 1998;44:351-6.
28. Campos LM, Kiss MH, D'Amico EA, et al. Antiphospholipid antibodies and antiphospholipid syndrome in 57 children and adolescents with systemic lupus erythematosus. Lupus 2003;12:820-6.
29. Male C, Mitchell L, Julian J, et al. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus. Blood 2001;97:844-9.
30. Massengill SF, Hedrick C, Ayoub EM, et al. Antiphospholipid antibodies in pediatric lupus nephritis. Am J Kidney Dis 1997;29:355-61.
31. Ravelli A, Caporali R, Di Fuccia G, et al. Anticardiolipin antibodies in pediatric systemic lupus erythematosus. Arch Pediatr Adolesc Med 1994;148:398-402.
32. Seaman DE, Londino AV, Kwoh CK, et al. Antiphospholipid antibodies in pediatric systemic lupus erythematosus. Pediatrics 1995;96:1040-5.
33. von Scheven E, Glidden DV, Elder ME. Anti-beta2-glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum 2002;47:414-20.
34. Montes de Oca MA, Babron MC, Blétry O, et al. Thrombosis in systemic lupus erythematosus: a French collaborative study. Arch Dis Child 1991;66:713-7.
35. Avcin T, Ambrozic A, Kuhar M, et al. Anticardiolipin and anti-ß2-glycoprotein I antibodies in sera of 61 apparently healthy children at regular preventive visits. Rheumatology 2001;40:565-73.
36. Andreoli L, Nalli C, Motta M, et al. Anti-ß2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: might it be the reason for their 'innocent' profile? Ann Rheum Dis 2011;70:380-3.
37. Giordano P, Tesse R, Lassandro G, et al. Clinical and laboratory characteristics of children positive for antiphospholipid antibodies. Blood Transfus 2012;10:296-301.
38. Arnaud L, Mathian A, Devilliers H, et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies. Autoimmun Rev 2015;14:192-200.
39. Arnaud L, Mathian A, Ruffatti A, et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev 2014;13:281-91.
40. Baca V, Garcia-Ramirez R, Ramirez-Lacayo M, et al. Cerebral infarction and antiphospholipid syndrome in children. J Rheumatol 1996;23:1428-31.
41. Mekinian A, Lachassinne E, Nicaise-Roland P, et al. European registry of babies born to mothers with antiphospholipid syndrome. Ann Rheum Dis 2013;72:217-22.
42. Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev 2010;10:74-9.
43. Asherson RA, Cervera R, de Groot PG, et al; Catastrophic Antiphospholipid Syndrome Registry Project Group. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003;12:530-4.
44. Cervera R, Font J, Gómez-Puerta JA, et al; Catastrophic Antiphospholipid Syndrome Registry Project Group. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis 2005;64:1205-9.
45. Berman H, Rodríguez-Pintó I, Cervera R, et al; Catastrophic Registry Project Group (European Forum on Antiphospholipid Antibodies). Pediatric catastrophic antiphospholipid syndrome: descriptive analysis of 45 patients from the 'CAPS Registry'. Autoimmun Rev 2014;13:157-62.
46. Haskin O, Amir J, Schwarz M, et al. Severe abdominal pain as a presenting symptom of probable catastrophic antiphospholipid syndrome. Pediatrics 2012;130:e230-5.
47. Cervera R, Rodríguez-Pintó I. G Espinosa on behalf of the Task Force on Catastrophic Antiphospholipid Syndrome. Catastrophic antiphospholipid syndrome: task force report summary. Lupus 2014;23:1283-5.
48. Berman H, Rodríguez-Pintó I, Cervera R, et al; Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies). Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 2013;12:1085-90.
49. Bayraktar UD, Erkan D, Bucciarelli S, et al. Catastrophic antiphospholipid syndrome project G. The clinical spectrum of catastrophic antiphospholipid syndrome in the absence and presence of lupus. J Rheumatol 2007;34:346-52.
50. Zikos TA, Sokolove J, Ahuja N, et al. Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome. J Clin Rheumatol 2015;21:311-3.
51. Barratt-Due A, Fløisand Y, Orrem HL, et al. Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. Rheumatology 2016;55:1337-9.
52. Lonze BE, Zachary AA, Magro CM, et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant 2014;14:459-65.
53. Shapira I, Andrade D, Allen SL, et al. Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis Rheum 2012;64:2719-23.
54. Kronbichler A, Frank R, Kirschfink M, et al. Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine 2014;93:e143.